Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients.
Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients.
复制标题
DOI：
10.1097/ppo.0000000000000251
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Bhardwaj N
中科院分区：
文献类型：
--
作者：
Balan S;Finnigan J;Bhardwaj N
树突状细胞具有感知危险信号、捕获、处理抗原并将其呈递给幼稚细胞或效应细胞的能力，对于诱导体液免疫和适应性免疫至关重要。成功的疫苗接种能够激活 DC，引发细胞和体液反应以及针对感兴趣目标的持久记忆反应。最近，很明显肿瘤细胞可以通过非同义突变或移码突变提供新的抗原来源，从而产生潜在的数百种突变衍生的肿瘤抗原（MTA）或新抗原。癌症患者体内已检测到识别 MTA 的 T 细胞，甚至可以导致肿瘤消退。设计 MTA 特异性疫苗接种策略必须考虑 DC 亚群的佐剂活性以及引发有效免疫反应的最佳配方。在这里，我们讨论人类 DC 引发 MTA 特异性反应的潜力。
Dendritic cells are equipped for sensing danger signals, capturing, processing and presenting antigens to naïve or effector cells and are critical in inducing humoral and adaptive immunity. Successful vaccinations are those that activate DC to elicit both cellular and humoral responses as well as long lasting memory response against the target of interest. Recently it has become apparent that tumor cells can provide new sources of antigens through non-synonymous mutations or frame-shift mutations, leading to potentially hundreds of mutation-derived tumor antigens (MTA) or neoantigens. T cells recognizing MTA have been detected in cancer patients and can even lead to tumor regression. Designing MTA-specific vaccination strategies will have to take into account the adjuvant activity of DC subsets and the best formulation to elicit an effective immune response. Here we discuss the potential of human DC to prime MTA-specific responses.